This Article Full Text Full Text (PDF) All Versions of this Article: 91/4/1284    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vottero, A. Articles by Ghizzoni, L. Search for Related Content PubMed PubMed Citation Articles by Vottero, A. Articles by Ghizzoni, L. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Anabolic Steroids Hazardous Substances DB LEUPROLIDE MENOTROPINS OXANDROLONE Related Collections Neuroendocrinology and Pituitary Pediatric Endocrinology

Final Height in Girls with Central Idiopathic Precocious Puberty Treated with Gonadotropin-Releasing Hormone Analog and Oxandrolone

Department of Pediatrics (A.V., S.P., M.V., B.P., S.B., L.G.), University of Parma, 43100 Parma, Italy; Department of Paediatric Medicine (M.C.), Paediatric Hospital Bambin Gesu’, 00165 Rome, Italy; and Department of Pediatric Endocrinology (S.L.), Ospedale Regionale per le Microcitemie, 09121 Cagliari, Italy

Address all correspondence and requests for reprints to: Lucia Ghizzoni, M.D., Department of Pediatrics, University of Parma, Via Gramsci 14, 43100 Parma, Italy. E-mail: lucia.ghizzoni{at}unipr.it.

Context: GnRH analogs (GnRHa) are considered the treatment of choice for central precocious puberty (CPP). During GnRHa administration, the suppression of the pituitary-gonadal axis results in decreased rates of linear growth and skeletal maturation and in improved adult height. However, in some patients, the growth deceleration is so marked that the expected improvement in predicted adult height is not achieved.

Objective: The objective of this study was to assess whether the addition of oxandrolone (Ox) may affect the height outcome of patients with CPP and growth deceleration during GnRHa treatment.

Design: This was an open-label, clinical study.

Setting: The study was performed at a pediatric endocrinology referral clinic.

Patients: Twenty patients with CPP and marked growth deceleration during GnRHa treatment were studied.

Interventions: Treatment consisted of GnRHa (Leuprorelina, 3.75 mg im every 28 d) alone (10 patients) or in combination with Ox (0.06 mg/kg·d by mouth) (10 patients).

Main Outcome Measure: The main outcome measure was the patients’ adult height.

Results: The adult height of the patients treated with GnRHa plus Ox was significantly higher than pretreatment predicted adult height (162.6 ± 2.3 vs. 154.8 ± 1.7 cm, mean ± SEM; P < 0.05) and target height (162.6 ± 2.3 vs. 158.0 ± 1.9; P > 0.05). Patients treated with GnRHa alone reached an adult height similar to the pretreatment predicted adult height (151.9 ± 1.2 vs. 155.4 ± 2.1 cm) but significantly lower than target height (151.9 ± 1.2 vs. 156.6 ± 1.4 cm; P < 0.005). No side effects were recorded in either group of patients.

Conclusions: Combined GnRHa and Ox therapy is a viable treatment option for children with CPP and marked growth deceleration during treatment with GnRHa alone.

This article has been cited by other articles:

				J.-C. Carel and J. Leger Precocious Puberty N. Engl. J. Med., May 29, 2008; 358(22): 2366 - 2377. [Full Text] [PDF]

				J. S. Sutherland, L. Spyroglou, J. L. Muirhead, T. S. Heng, A. Prieto-Hinojosa, H. M. Prince, A. P. Chidgey, A. P. Schwarer, and R. L. Boyd Enhanced Immune System Regeneration in Humans Following Allogeneic or Autologous Hemopoietic Stem Cell Transplantation by Temporary Sex Steroid Blockade Clin. Cancer Res., February 15, 2008; 14(4): 1138 - 1149. [Abstract] [Full Text] [PDF]